000045393 001__ 45393
000045393 005__ 20200423204109.0
000045393 0247_ $$2DOI$$a10.1149/1.1865592
000045393 0247_ $$2WOS$$aWOS:000228326500006
000045393 0247_ $$2ISSN$$a1099-0062
000045393 0247_ $$2ISSN$$a1944-8775
000045393 0247_ $$2Handle$$a2128/2882
000045393 037__ $$aPreJuSER-45393
000045393 041__ $$aeng
000045393 082__ $$a540
000045393 084__ $$2WoS$$aElectrochemistry
000045393 084__ $$2WoS$$aMaterials Science, Multidisciplinary
000045393 1001_ $$0P:(DE-Juel1)VDB3067$$aSchober, T.$$b0$$uFZJ
000045393 245__ $$aComposites of ceramic high-temperature proton conductors with inorganic compounds
000045393 260__ $$aPennington, NJ$$bSoc.$$c2005
000045393 300__ $$aA199 - A200
000045393 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000045393 3367_ $$2DataCite$$aOutput Types/Journal article
000045393 3367_ $$00$$2EndNote$$aJournal Article
000045393 3367_ $$2BibTeX$$aARTICLE
000045393 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000045393 3367_ $$2DRIVER$$aarticle
000045393 440_0 $$013562$$aElectrochemical and Solid State Letters$$v8$$x1099-0062$$y4
000045393 500__ $$aRecord converted from VDB: 12.11.2012
000045393 520__ $$aThis open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
000045393 536__ $$0G:(DE-Juel1)FUEK242$$2G:(DE-HGF)$$aKondensierte Materie$$cM02$$x0
000045393 588__ $$aDataset connected to Web of Science, Pubmed
000045393 650_7 $$2WoSType$$aJ
000045393 773__ $$0PERI:(DE-600)1483551-4$$a10.1149/1.1865592$$gVol. 8, p. A199 - A200$$pA199 - A200$$q8<A199 - A200$$tElectrochemical and solid-state letters$$v8$$x1099-0062$$y2005
000045393 8567_ $$uhttp://hdl.handle.net/2128/2882$$uhttp://dx.doi.org/10.1149/1.1865592
000045393 8564_ $$uhttps://juser.fz-juelich.de/record/45393/files/68987.pdf$$yOpenAccess
000045393 8564_ $$uhttps://juser.fz-juelich.de/record/45393/files/68987.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000045393 8564_ $$uhttps://juser.fz-juelich.de/record/45393/files/68987.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000045393 8564_ $$uhttps://juser.fz-juelich.de/record/45393/files/68987.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000045393 909CO $$ooai:juser.fz-juelich.de:45393$$pdnbdelivery$$pVDB$$pdriver$$popen_access$$popenaire
000045393 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000045393 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000045393 9141_ $$y2005
000045393 9131_ $$0G:(DE-Juel1)FUEK242$$bMaterie$$kM02$$lKondensierte Materie$$vKondensierte Materie$$x0
000045393 9201_ $$0I:(DE-Juel1)VDB321$$d31.12.2006$$gIFF$$kIFF-IEM$$lElektronische Materialien$$x0
000045393 970__ $$aVDB:(DE-Juel1)68987
000045393 980__ $$aVDB
000045393 980__ $$aJUWEL
000045393 980__ $$aConvertedRecord
000045393 980__ $$ajournal
000045393 980__ $$aI:(DE-Juel1)PGI-7-20110106
000045393 980__ $$aUNRESTRICTED
000045393 980__ $$aFullTexts
000045393 9801_ $$aFullTexts
000045393 981__ $$aI:(DE-Juel1)PGI-7-20110106